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ABSTRACT
Aims: The aim of the current study was to establish a simple and yet as much as possible
physiologic approach for a simulation of the pulmonary absorption process to compare
different inhaled drugs or drug formulations.
Methodology: We designed a dialysis setting that allowed monitoring the drug release
from human lung tissue into a continuous-flow plasma compartment. For proof-of-concept
experiments we chose the glucocorticoid fluticasone propionate (FP) as model compound.
For subsequent experiments we selected a commercially available metered dose inhaler
delivering a fixed combination of the short-acting ß2-agonist fenoterol and the muscarinicantagonist ipratropium bromide.
Results: With the novel dynamic dialysis model we observed high drug transport rates
from the lung tissue into plasma including an elimination phase. The concentration profile
in the plasma compartment of our model system was similar to the plasma concentration
courses after inhalation of FP. Compared to FP significantly higher drug fractions of
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fenoterol and ipratropium bromide were released into plasma and the transfer of
ipratropium was more pronounced compared to fenoterol. Again, concentration profiles in
plasma were alike to those described in clinical studies.
Conclusion: We suggest that this model is appropriate for rapid assessment of
comparative diffusion behaviour of drugs or drug formulations from lung tissue into
plasma.
Keywords: Pulmonary absorption; bronchial tissue; human; fluticasone propionate;
fenoterol; ipratropium bromide.
1. INTRODUCTION
The efficacy and safety of inhaled drugs are dependent on the compounds’
pharmacokinetics which in turn is governed by the physicochemical properties of the drug
and by its formulation. Additionally, the percentage of lung deposition and regional
deposition patterns in the lungs are important factors which determine the clinical response
to compounds exerting local effects in the lung such as anti-inflammatory or bronchodilating
activity [1]. Up to 60-90% of an inhaled drug are deposited in the oropharyngeal region and
are subsequently swallowed [2]. Analysis of pulmonary deposition and regional particle
distribution can be achieved by gamma scintigraphy after inhalation of radiotracer-labeled
drugs. However, this complex method is typically not applicable for routine measurements. It
has been proposed that pharmacokinetic data well reflect pulmonary drug deposition and
that pulmonary drug absorption can be elucidated using pharmacokinetic methods [2].
Recently, pharmacokinetic data have been discussed as key indicator of bioequivalence for
inhaled drug products [3].
For assessment and comparative analysis of pulmonary drug absorption various in vivo, ex
vivo and in vitro model systems have been used [4,5]. Each model has inherent advantages
and disadvantages and typically allows the detailed investigation of single or multiple
individual stages of pulmonary drug absorption. We previously developed a dialysis model
that allowed monitoring the particle dissolution and diffusion kinetics from human lung tissue
into human plasma [6]. In this simple experimental setting we were able to discern the
diffusion time courses of two different commercially available formulations of
beclomethasone dipropionate delivered by metered dose inhalers (MDIs). Subsequently, we
compared the diffusion kinetics of a liposome formulation and a propylene glycol solution of
cyclosporine A. The results we obtained with the dialysis model were in excellent agreement
with those of a permeability assay using the human bronchial cell line Calu-3 [7]. This
suggested that this dialysis model was appropriate for simulation of pulmonary absorption
processes and comparative evaluation of different drugs or drug formulations. However, one
very obvious disadvantage of this dialysis as well as of cell culture permeability assays was
the non-physiologic accumulation of the drug in the acceptor compartment. Though sink
conditions were maintained during the dialysis and permeability experiments an elimination
phase was absent.
The aim of the current study was to modify the static dialysis setting to allow the
determination of cmax and tmax data and thus establish a more physiologic approach for asimulation of the pulmonary absorption process. Therefore, we designed the acceptor
chamber as a flow-through cell to be connected to a fraction collector. For first proof-of-
concept experiments we chose the glucocorticoid fluticasone propionate (FP) as model
compound since data from clinical inhalation studies were available. Higher flux rates have
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been described for continuous flow systems compared to side-by-side systems [8]. For
subsequent experiments we selected a commercially available aerosol delivering a fixed
combination of the short-acting 2-agonist fenoterol and the muscarinic antagonistipratropium bromide (Berodual® N). So far, no pharmacokinetic in vivo study with this drug
combination has been published. Clinical data has been published for single inhaled
fenoterol [9] and ipratropium bromide [10] which would thus allow comparison with the
results of our modified dialysis model.
2. MATERIALS AND METHODS
2.1 Chemicals and Reagents
Fluticasone propionate (FP) was a generous gift from GlaxoSmithKline (Greenford,
England), amcinonide, fenoterol hydrobromide (Feno-HBr), ipratropium bromide (Ipra-Br),
salbutamol sulfate (Salb-S) and the dye Fast Green FCF were purchased at Sigma Aldrich
(Taufkirchen, Germany). The metered dose inhaler (MDI) Berodual® (Boehringer Ingelheim
Pharma GmbH & Co. KG, Ingelheim, Germany), delivering 50µg Feno-HBr and 20µg Ipra-Br
per puff, was bought at a local community pharmacy. Diethylether (HPLC quality) and
acetonitrile (HPLC quality) were purchased at VWR Prolabo® (Darmstadt, Germany). N-(2-
hydroxyethyl) piperazine-N´-2-ethanesulfonic acid (HEPES) was purchased from GERBU
(Heidelberg, Germany) and a stock solution containing 10,000IU/mL penicilline and
10,000µg/mL streptomycine in 0.9%NaCl from Biochrom AG (Berlin, Germany). All other
chemicals were obtained from E. Merck (Darmstadt, Germany). Water was obtained from a
Millipore® water purification unit.
2.2 Source and Handling of Human Specimen
Human lung tissue specimen was obtained from patients with bronchial carcinomas who had
to undergo lobectomy, bilobectomy or pneumonectomy and who gave informed consent.
The use of human lung tissue was approved by the ethics committee of the Medical Faculty
of the University of Würzburg. Only cancer-free tissue was used for the experiments. The
resected lung lobe underwent visual inspection by the surgeon who excised cancer-free
tissue samples most distant from the tumor.
Tissue samples were shock frozen in liquid nitrogen after resection and stored at -80 °C until
usage. To collect sufficient material for the experiments, tissue samples of at least three
patients were pooled. Tissue was either cut into small pieces of approximately 1 mm3 (for
experiments with Feno-HBr/Ipra-Br) or homogenized (for experiments with FP). Therefore,
one part of the tissue pieces was homogenized in two parts of Krebs-Ringer-HEPES buffer
(118mM NaCl, 4.84mM KCl, 1.2mM KH2PO4, 2.43mM MgSO4x6 H2O, 2.44mM CaCl2x2 H2Oand 10mM HEPES; pH=7,4). Penicilline-streptomycine solution was added to the buffer
achieving a final concentration of 10IU/mL penicilline and 10µg/mL streptomycine.
Homogenization was performed under continuous cooling using an Ultra-Turrax® (Janke &
Kunkel, Staufen, Germany). Before starting the series of dialysis experiments the required
amount of human lung tissue pieces or homogenate was calculated and a sufficient amount
was prepared and divided into aliquots. Since all aliquots descended from this preparation
protein content and enzymatic activity of the homogenate was identical for each experiment.
Human plasma was obtained from a local blood bank (Transfusionsmedizin, Würzburg,
Germany). Plasma samples were shock frozen in liquid nitrogen and stored at -80°C until
usage.
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2.3 Dialysis Experiments
Static dialysis experiments were performed as described in detail previously [6,7]. Briefly, the
dialysis unit (designed by our group) consisted of two individual tightly fitting Teflon
chambers separated by a dialysis membrane. One chamber was prepared for the minced
lung tissue, the other chamber was supposed to be filled with human plasma. The chamber
for plasma had two apertures, one for obtaining dialysis samples and one for addition of
fresh plasma. For the dynamic dialysis experiments the experimental setting was modified.
The upper dialysis chamber was constructed as a flow-through unit with two stainless steel
capillaries at opposing ends of the inner unit (Fig. 1).
Fig. 1. Schematic experimental setting of the dynamic dialysis model. A: Application
of the dose to human lung tissue pieces. The MDI was actuated over the tissue
reservoir. The reservoir was covered with a dialysis membrane and closed by
attaching the upper acceptor chamber for plasma. B: Human plasma was
continuously pumped through the dialysis unit. C: The dialysis unit was kept at 37°C
and gently shaken throughout the experiment. D: A fraction collector sampled the
plasma that passed the upper chamber of the dialysis unit
A
B
37ºC
C
D
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This allowed a continuous flow of human plasma through the upper dialysis chamber. The
flow was driven by a peristaltic pump (Minipuls 2; Gilson, Villiers-le-Bel, France) at a rate of
0.38mL/min. After passing the upper chamber plasma was collected by a fraction collector
(Waters Fraction Collector 40109, Advantec SF-2120, Advantec, Ontario, Canada) at
sampling intervals of 3min. The dialysis unit was kept at 37°C (heating cabinet Model 400;
Memmert, Schwabach, Germany) and gently shaken (Mini Rocker Bio MR-1; Bio San, Riga,
Latvia) throughout the experiment. The bronchodilator drug combination was applied from
the commercially available aerosol device (Berodual® N) onto the lung tissue pieces (cubes
of about 1mm3) as described earlier [6]. Briefly, a dosing device (designed by our group) that
was composed of a fitting for the MDI, and a glass cylinder to assure reproducible dosing
conditions was used. The MDI was actuated and the time in which the particle cloud was
allowed to sediment was kept constant. The lung tissue pieces were briefly stirred with a
pipette tip. For the proof-of-concept experiments with fluticasone propionate 200µg of the
compound was added as a methanol solution to lung tissue preparation which was then
briefly stirred. Subsequently, a pre-conditioned dialysis membrane (Spectra/Por® 6, MWCO
2000, Spectrum Laboratories, Rancho Dominguez, USA) was placed on the chamber; the
dialysis unit was closed by attaching the second chamber. Collected plasma samples were
stored at -20°C until analysis. Only plasma fractions obtained after 3, 6, 15, 21, 30, 45, 60,
90, 120, 150, 180 and 240min were analysed.
2.4 Analysis of Fluticasone Propionate Concentrations by HPLC
The analysis of fluticasone propionate was similar to the previously described method for
glucocorticoids [6]. Briefly, 50µL of internal standard solution (amcinonid 5µg/mL in
methanol) was added to a 1mL plasma sample. Samples were extracted twice with 3mL
diethylether for 20min using a roller mixer. The combined organic phases were evaporated
to dryness under a gentle stream of nitrogen at 30°C. The resulting residue was
reconstituted in 0.2mL methanol and analyzed by liquid chromatography using a Waters
HPLC (Milford, USA) consisting of a 1525 binary pump, a 717 plus autosampler and 2487
dual wavelength absorbance detector. Data collection and integration were accomplished
using Breeze™ software version 3.30. Analysis was performed on a Symmetry C18 column
(150x4.6mm I.D., 5µm particle size, Waters, USA). Typically, 20µL of sample were injected,
a flow rate of 1 mL/min was used, and detection wavelength was set to 254nm. Mobile
phase consisted of water containing 0.2% (v/v) acetic acid (A) and acetonitrile (B). The
gradient elution started at 60% eluent A, decreasing linearly to 29% A by 30min.
2.5 Analysis of Fenoterol and Ipratropium Concentrations by LC-MS/MS
The analysis of fenoterol and ipratropium was similar to the previously described method for
2-agonists [11]. Briefly, 50µL of internal standard solution (salbutamol 1µg/mL in methanol)was added to a 1mL plasma sample. Proteins were precipitated by addition of 3mL
acetonitrile and vortexing for 30 s. After centrifugation the supernatant was evaporated to
dryness under a gentle stream of nitrogen. The resulting residue was reconstituted in 0.4mL
methanol / water (1:9), centrifuged and subjected to LC-MS/MS analysis. High-performance
liquid chromatography-MS/MS analyses were performed on an Agilent 6460 triple-
quadrupole mass spectrometer (Agilent Technologies, Waldbronn, Germany) with an
electrospray interface coupled to an Agilent Technologies ultra-high-performance liquid
chromatograph. Chromatographic separations were carried out using a XTerra MS C18
column (Waters; 3.0x150mm, 3.5µm particle size, with guard column) with the following
solvent systems: solvent A= 0.1% formic acid in Millipore® water and solvent B= acetonitrile.
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A linear step gradient elution was performed: 5% to 100% B in 8min (flow rate 0.5mL/min).
Typically, 10µL of the sample was injected. The electrospray interface source was operated
in positive ionization mode (ESI+) at a capillary voltage of 3.50kV and a desolvation
temperature of 300°C. Quantification was performed using multiple reaction monitoring
(MRM mode). Fragmentation voltages (V) and collision energy (eV) are displayed in Table 1.
Nitrogen was used as the desolvation and cone gas.
Table 1. Settings of MRM (multiple reaction monitoring) mode for LC-MS/MS analysis
of fenoterol and ipratropium
Channel Compound Precursor
(m/z)
Fragment
(m/z)
Fragmentation
voltage (V)
Collision
energy (eV)
1 Fenoterol 304 107* 120 33
2 135 17
3 Ipratropium 332 124 180 33
4 166* 25
5 Salbutamol
(ISD)
240 148* 100 17
6 222 5
* -Quantifier; ISD: internal standard
The effectively deposited doses in the lung tissue depot were determined as described
earlier in detail [6]. Briefly, after addition of the internal standard the MDI mouthpiece and the
glass cylinder of the dosing device (Fig. 1) were rinsed with 4 mL methanol and 4mL water.
Washing solutions were collected in a 10 mL volumetric standard flask. Water was added to
yield 10.0mL solution which was analysed by LC-MS/MS.
3. RESULTS
3.1 Establishment of the Dynamic Dialysis with Fluticasone Propionate
Fluticasone propionate (FP; 200µg) was administered as solution to the lung tissue and
diffusion into human plasma was monitored in the static and dynamic dialysis setting. In the
static dialysis experiments the concentration of FP increased continuously from 45±13ng/mL
after 3min to 739±11ng/mL after 240min Fig. 2. In contrast, in the dynamic dialysis setting
the FP concentrations in plasma increased from 36±6ng/mL after 3min to reach a maximum
of 100±7ng/mL after 30min. Thereafter, the plasma levels steadily decreased to 50±5ng/mL
after 240min.
3.2 Dialysis Experiments with Fenoterol and Ipratropium Bromide
The combination of fenoterol hydrochloride and ipratropium bromide was administered to the
lung tissue pieces via a commercially available MDI (Berodual® N). Effective doses of
60.8±9.4µg (31±5% of the nominal dose) fenoterol base and 36.6±6.2µg (37±6% of the
nominal dose) of ipratropium were deposited in the lung tissue chamber (Table 2). Of
fenoterol, 52.1±0.7µg were retained in the device’s mouthpiece and 62.7±4.2µg were
recovered from the glass cylinder of the dosing device (Fig. 1). Likewise, of ipratropium
17.7±0.3µg were retained in the device’s mouthpiece and 20.7±3.3µg were recovered from
the glass cylinder. Thus, about one third of the respective nominal doses were deposited on
the tissue, the rest was retained in the mouthpieces and deposited on the glass cylinder.
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Fig. 2. Diffusion of fluticasone propionate (FP) from human lung tissue into human
plasma. The proof-of-concept experiment compared the results of a static dialysis
without continuous plasma exchange in the upper chamber of the dialysis unit with
the dynamic dialysis setting. Data points represent mean and mean deviation of the
mean of triplicate experiments
Table 2. Percentages of the dose delivered by the device (Berodual® N) deposited in
the device’s mouthpiece, the glass cylinder and the depot for the lung homogenate.
Data represent the mean and mean deviation of the mean of n=3 / n=4 experiments
Deposition [% of nominal dose] Fenoterol Ipratropium
Bromide
Device’s mouthpiece 26±0 18±0
Glass cylinder 32±2 21±3
Depot for lung tissue 31* ±5 37* ±6
* n=4 experiments
In the dynamic dialysis setting fenoterol rapidly diffused from the lung tissue pieces into
human plasma (Fig. 3). Panel A. Fenoterol concentrations in plasma increased from
96±7ng/mL (0.76±0.05% of the deposited dose) after 3min to reach a maximum of
234±26ng/mL (1.84±0.21% of the deposited dose) after 30min. Thereafter, the plasma levels
steadily decreased to 125±9ng/mL (0.99±0.07% of the deposited dose) after 240min. The
area under the curve (AUC) was calculated as 340±24% of the deposited dosexmin.
Ipratropium concentrations in plasma increased from 74±11ng/mL (0.97±0.15% of the
deposited dose) after 3min to reach a maximum of 201±34ng/mL (2.64±0.45% of the
deposited dose) after 30min (Fig. 3. Panel A). Thereafter, the plasma levels steadily
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decreased to 69±10ng/mL (0.91±0.13% of the deposited dose) after 240min. The AUC was
calculated as 426±55% of the deposited dosexmin. Differences between plasma
concentrations of fenoterol and ipratropium expressed as % of the deposited dose were
most pronounced between 15 and 120min.
Fig. 3. Panel A: Diffusion of fenoterol and ipratropium bromide from human lung
tissue into human plasma using the dynamic dialysis setting. To directly compare the
diffusion processes of the bronchodilators with fluticasone propionate (FP) values are
expressed as percentage of the nominal dose that was applied to the lung tissue
pieces. Data points represent mean and mean deviation of the mean of triplicate
experiments. Panel B: Pulmonary absorption of fenoterol and fluticasone propionate
(FP) after inhalation. Data points were extracted from clinical studies reporting the
inhaled administration of 200 and 400µg fenoterol [9] and 1000µg FP [19]. To directly
compare the pulmonary absorption of both drugs the reported plasma concentrations
were normalized to a 500µg dose. For fenoterol the darker diamont symbols represent
the normalized plasma concentrations after inhalation of 200µg, the lighter square
symbols the normalized plasma concentrations after inhalation of 400µg
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For comparison, FP plasma concentrations from the dynamic dialysis experiments are
shown as % of the deposited dose as well (Fig. 3. Panel A). Concentrations increased from
0.09±0.01% of the deposited dose after 3min to reach a maximum of 0.24±0.02% of the
deposited dose after 30min. Thereafter, the plasma levels steadily decreased to 0.12±0.01%
of the deposited dose after 240min.
To parallel the results from the dynamic dialysis setting, data from clinical studies were
extracted and displayed in Fig. 3, Panel B. In a pharmacokinetic study with fenoterol, 200
and 400µg were administered as inhaled formulation and plasma concentrations were
determined [9]. In another study, 1000µg FP was inhaled [19]. To compare the plasma
concentration profiles we normalized the reported concentrations to a dose of 500µg of the
respective drug.
4. DISCUSSION
In the current study we established a new model for comparative evaluation of the diffusion
kinetics of inhaled drugs from human lung tissue into human plasma. Therefore, we
designed a dialysis chamber that allowed the release of a drug fraction from the human lung
tissue into a continuous-flow plasma compartment. This new experimental setting allowed a
more physiologic simulation of the pulmonary absorption process. Using a commercially
available aerosol formulation we were able to describe for the first time the comparative
diffusion behavior of fenoterol and ipratropium from a lung tissue preparation into plasma.
We suggest that this model is appropriate for rapid assessment of the lung retention
characteristics of different drugs or drug formulations.
Model systems with continuous flows have been described before and they have been
utilized for determination of drug absorption from the gastrointestinal tract [12,13], through
other mucosal tissues or the skin [8,14]. These models can be used e.g. for studying the role
of absorption enhancers and for analysis of drug bioavailability or bioequivalence studies
[13]. Recently, a continuous flow-through diffusion system for bronchial tissue has been
described [15]. Typically, in these model systems tissue sections with external diameters
between 4 and 10 mm are mounted on flow-through cells. The drug is then deposited in the
donor chamber and diffuses through the tissue disk into the receiving flow-through chamber.
Clear advantages of these systems are that the physiologic tissue integrity is maintained and
that permeability data can be collected over a prolonged time such as 24 hours. Usually
a steady state of the flux is reached after a few hours. It has been pointed out that the
small tissue area reduces the drug flux and thus permits low flow rates in the acceptor
chamber [8].
The approach we chose differed from the previously reported continuous flow systems. We
utilized lung tissue pieces of about 1mm3 that filled the lower dialysis chamber of 4.8mL. The
donor and acceptor chambers were separated by a standard dialysis membrane which
molecular weight cut-off was chosen large enough as to not present a diffusion barrier to the
drugs. Thus, compared to the other systems it was not compulsory for the drug to permeate
the tissue sections to reach the receiving chamber. The diffusion in our model was mainly
governed by the tissue adsorption and desorption processes. However, we recently
demonstrated that the diffusion kinetics we determined for two different cyclosporine a
formulations in our static dialysis model was very consistent with the permeability data
obtained with a Calu-3 cell culture model [7].
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In the current study we aimed at a more pronounced drug transfer from the lung tissue into
the plasma compartment and to simulate an elimination phase. Specifically, we wanted to
modify the static dialysis model to that effect that it more closely mirrored a plasma
concentration profile as it is seen In vivo after inhalation of a drug. For the initial proof-of-
concept experiments we compared the diffusion of fluticasone propionate (FP) in the static
and dynamic flow-through dialysis system. As expected, the differences in the release
characteristics from the human lung tissue were striking. As previously seen with
beclomethasone dipropionate and cyclosporine A [6,7] we found a continuous accumulation
of FP in the acceptor chamber during the static dialysis. Still, sink conditions prevailed over
the whole experimental period with drug concentrations in the acceptor chamber being
significantly less than 10% of that in the donor chamber. The concentration of FP in the
plasma compartment steadily increased over time without reaching a clear plateau phase
after 240min. In contrast, higher drug transport rates as reflected by an increase and
subsequent decrease of drug concentrations were observed in the dynamic dialysis setting.
This is consistent with the report of higher flux rates of continuous flow systems compared to
side-by-side systems [8]. The concentration profile in the plasma compartment of our model
system was similar to the plasma concentration courses after inhalation of single doses FP
by healthy volunteers [16-19]. In our flow-through system we determined a tmax of 0.5h forFP. The tmax values reported in clinical studies varied between 0.3h and 0.6h (doses of 250and 500µg, respectively, FP [16]), 0.9h (1000µg FP [19]), 1.5h (200 or 500µg FP [17]) and 1-
2h (1000µg FP [18]). Thus, the tmax data recorded in our model was within the range ofreported In vivo results. Furthermore, it has to be considered that we applied FP as solution
to lung tissue which would accelerate the distribution process and yield smaller tmax values
compared to clinical studies in which the drug was delivered as solid particles that required
dissolution before pulmonary absorption. In contrast to the tmax the t½ of 3.5h we calculatedfrom the data in our model deviated more pronounced from In vivo data. In clinical studies
reported t½ values varied between 5.1h (after a dose of 200µg FP [17]), 5.2h (250µg FP[16]), 5.9h (500µg FP [16]), 5.7h (1000µg FP [19]), and 10.1h (500µg [17]).
After the initial experiments with FP we used the dynamic dialysis model to analyse for the
first time the diffusion of fenoterol and ipratropium bromide from human lung tissue into
plasma after simultaneous delivery of both compounds by a commercially available MDI
(Berodual® N). To compare the diffusion characteristics of both drugs the plasma
concentrations were expressed as percent of the dose administered to the lung tissue.
Between 15 and 120min higher fractions of ipratropium bromide were released into plasma
as compared to fenoterol which might be due to the relative higher lipophilicity of fenoterol
(log P=1.36 [20]) compared to ipratropium (log P=0.89 [20]). A lately reported continuous
flow-through diffusion system for bronchial tissue also investigated the diffusion behaviour of
ipratropium bromide and the 2-agonist salbutamol [15]. The flux of ipratropium bromideacross bronchial tissue was always slightly above the flux of salbutamol and both drugs
reached a steady state flux rate after approximately 14 h. Since salbutamol and fenoterol are
structurally related the slightly higher permeability of the 2-agonist compared to theanticholinergic drug appears to be consistent with our observations. There were some
distinct differences between our dynamic dialysis system and the flow-through diffusion
model of van Zyl et al. [15]. Besides the fact that they used porcine lungs their bronchial
tissue area was roughly 4000fold smaller compared to ours (0.039cm2 versus 15.9cm2), the
flow rate was approximately 15fold lower (1.5ml/h versus 22.8ml/h), and the drug
concentration in the donor chamber was higher with 1mg/mL compared to our 0.013mg/mL
(fenoterol) and 0.008mg/mL (ipratropium bromide). These differences obviously contributed
to a higher drug transfer in our experiments which again resulted in the simulation of an
elimination phase. Both fenoterol and ipratropium displayed a tmax of 30min. This was a later
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tmax compared to human In vivo studies in which both compounds evinced a tmax after
approximately 15min [9,10]. It is possible that the pulmonary absorption of fenoterol and
ipratropium is enhanced by drug transporters In vivo. Though no information has been
published about fenoterol in this respect, the structurally related salbutamol is a known
substrate of drug transporters located in the lung [21]. Likewise, it was reported that
ipratropium bromide absorption is mediated by organic cation transporters [22]. As a matter
of course this process would not be adequately mirrored by our dialysis model. In our
dynamic model the calculated t½ were of 3.5h for fenoterol and 2.5h for ipratropium bromide.For comparison, in clinical studies a t½ of 3.3h was reported for fenoterol [9] and 1.5h foripratropium bromide [10]. Although the dynamic dialysis model cannot predict exact
pharmacokinetic data it is appropriate for relative assessment of drug diffusion processes in
the lung. It might be used for comparative screening and evaluation of different drugs or drug
formulations. This notion is further supported by the summarized data of fluticasone
propionate (FP), fenoterol and ipratropium bromide. When the measured concentrations in
the plasma compartment are expressed as percent of the dose effectively applied to the lung
tissue it becomes evident that significantly lower drug fractions of the highly lipophilic FP
were distributed into plasma as compared to the hydrophilic 2-agonist and theanticholinergic drug.
5. CONCLUSION
To summarize, we developed a novel dynamic dialysis model that allows the simulation of a
pulmonary absorption process included an elimination phase of the drug. Furthermore,
commercially available drug formulations such as aerosols can be used with this model for
combined assessment of the drug’s dissolution and diffusion characteristics.
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